Abstract. Neoadjuvant chemotherapy with docetaxel for advanced breast cancer can improve the radicality for a subset of patients, but some patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting responses to docetaxel, we analyzed gene expression profiles of biopsy materials from 29 advanced breast cancers using a cDNA microarray consisting of 36,864 genes or ESTs, after enrichment of cancer cell population by laser microbeam microdissection. Analyzing eight PR (partial response) patients and twelve patients with SD (stable disease) or PD (progressive disease) response, we identified dozens of genes that were expressed differently between the 'responder (PR)' and 'nonresponder (SD or PD)' groups. We further selected the nine 'predictive' genes showing the most significant differences and established a numerical prediction scoring system that clearly separated the responder group from the non-responder group. This system accurately predicted the drug responses of all of nine additional test cases that were reserved from the original 29 cases. Moreover, we developed a quantitative PCR-based prediction system that could be feasible for routine clinical use. Our results suggest that the sensitivity of an advanced breast cancer to the neoadjuvant chemotherapy with docetaxel could be predicted by expression patterns in this set of genes.
Introduction
Neoadjuvant systemic treatment before surgery for advanced breast cancer is one of the most crucial factors in reducing mortality (1, 2) . However, although the estrogen-receptor status is predictive of response to hormonal treatments, there are no clinically useful markers to predict responses to chemotherapy. Therefore, all patients who are eligible for chemotherapy receive the same treatment, even though de novo drug resistance results in failures of the treatment in many cases. Docetaxel is one of the most commonly used anticancer agents in the treatment of breast cancer. It binds to ß-tubulin, one of the major components of microtubules. It exerts its growth inhibitory effects by stabilizing microtubules, which arrests the growth of tumor cells at the G2-M phase (3) . Docetaxel has been widely used for treatment of metastatic breast cancers (4) and its application for primary breast cancers in the adjuvant and the neoadjuvant settings has also been indicated (5) .
However, since no method is yet available to predict responses of individual patients to docetaxel chemotherapy, some patients suffer from adverse reactions of the drug without having any clinical benefit and often lose an opportunity for additional therapy when their physical condition deteriorates (6, 7) . Hence, development of a method to predict the effectiveness of a specific therapy is of critical importance for patients with advanced breast cancer. Certain factors were reported to be associated with chemosensitivity or prognosis, but application of only one or a few of such factors has failed to reliably predict individual responses and it is obvious that a larger body of information is required toward establishment of a clinically applicable method.
Profiling of gene expression patterns on genome-wide cDNA microarrays enables investigators to perform comprehensive characterization of molecular activities in cancer cells. Systematic analysis of expression levels for thousands of genes is also a useful approach for identifying molecules related to response to anticancer drugs or radiation.
We have been attempting to establish systems based on gene expression profiling that would allow accurate prediction of responses to chemotherapeutic agents in diseases such as acute lymphoblastic leukemia and bladder cancer (8, 9) . In the study reported here, we established a system for predicting response to docetaxel neoadjuvant chemotherapy among patients with advanced breast cancer, using genome-wide information obtained for 29 cases on a cDNA microarray consisting of 36,864 transcribed elements in combination with laser microbeam microdissection of the tumors to obtain pure populations of cancer cells for analysis. We identified nine genes that showed significantly different levels of expression between the responder and non-responder groups of breast cancer patients who were treated with a neoadjuvant docetaxel monotherapy. We suggest that such information may lead ultimately to our goal of 'personalized treatment'. RNA extraction and T7-based RNA amplification. Total RNAs were extracted from each population of microdissected cancer cells, as described previously (10) . To guarantee the quality of RNAs, total RNA extracted from the residual tissue of each case were electrophoresed on a denaturing agarose gel and quality was confirmed by the presence of rRNA bands. Extraction of total RNA and T7-based RNA amplification were done, as described previously (11), except that we used RNeasy micro kits (Qiagen, Valencia, CA). After two rounds of RNA amplification, we obtained 50 to 550 μg of amplified RNA for each sample. A mixture of ductal cells in breast tissues from seven patients was prepared as a universal control and was amplified in the same way. RNA amplified by this method accurately reflects the proportions in the original RNA source, as we had confirmed earlier by semiquantitative reverse transcription-PCR (RT-PCR) experiments (10) , in which data from the microarrays were consistent with results from RT-PCR regardless of whether total RNAs or amplified RNAs were used as templates.
Materials and methods

Patients
cDNA microarray. To obtain cDNAs for spotting on the glass slides, we performed RT-PCR amplification for each gene, as described previously (10) . The PCR products were spotted on Alice glass slides O,R (GE Healthcare, Amersham Biosciences, Buckinghamshire, UK) with a high-density Microarray Spotter Lucidea (GE Healthcare, Amersham Biosciences); 9,216 genes were spotted in duplicate on a single slide. We prepared four different sets of slides (a total of 36,864 gene spots), on each of which the same 52 housekeeping genes and two negative control genes were spotted as well. The cDNA probes were prepared from amplified RNA using the method described previously (11) . For hybridization experiments, 2.5 μg of amplified RNAs from each patient and from the control were reversely transcribed in the presence of Cy5-dCTP and Cy3-dCTP (GE Healthcare BioSciences), respectively. Hybridization, washing and detection of signals were carried out, as described previously (11) .
Quantification of signals.
We quantified the signal intensities of Cy3 and Cy5 from the 36,864 spots and analyzed the signals by substituting backgrounds, using ArrayVision software (Imaging Research, Inc., St. Catharines, Ontario, Canada). Subsequently, the fluorescence intensities of Cy5 (breast cancer cells) and Cy3 (control) for each target spot were adjusted so that the mean Cy5/Cy3 ratio of the 52 house-keeping genes became one. Because the data with low signal intensities are less reliable, we defined a cutoff value for the data on each slide as described previously (12) and excluded genes from further analysis when both Cy3 and Cy5 signalintensities were lower than the cutoff value (12) . For genes for which either or both of the signal-intensities were above the cutoff value, we calculated the ratio of Cy5/Cy3 signals as a relative expression ratio using the raw data of each sample. However, if either of the Cy3 or Cy5 signal intensity was lower than the cutoff value, the Cy5/Cy3 ratio might be calculated to an extremely high or low and lead to make a significant false-influence for the further analysis. Hence, when either Cy3 or Cy5 signal intensity was less than the cutoff value, we adjusted the lower one to be half of each cutoff value plus the signal intensities and then calculated the Cy5/Cy3 ratios.
Hierarchical clustering analysis. We used web-available software ('Cluster' and 'TreeView') written by M. Eisen (http://genome-www5.stanford.edu/MicroArray/SMD/ restech.html) to create a graphic representation of the microarray data and to create a dendrogram of hierarchical clustering. Before the clustering algorithm was applied, the fluorescence ratio for each spot was first log-transformed and then the data for each sample were median-centered to remove experimental biases.
Extraction of genes for predicting the chemosensitivity.
We applied a random permutation test to identify genes that were expressed at a significantly different level between the two groups, that is, tumors with good response and those with poor response to the chemotherapy. Mean (μ) and standard deviation (‰) were calculated from the log transformed relative expression ratios of each gene in responder (r) and nonresponder (n) cases. A discrimination score (DS) for each gene was defined as follows:
We carried out permutation tests to estimate the ability of individual genes to distinguish the two groups; samples were randomly permutated between the two groups 10,000 times. Because the DS data set of each gene showed a normal distribution, we calculated a P-value for the user-defined grouping (13) . For the initial analysis, we applied the expression data for original 20 cases consisting of 8 responders and 12 non-responders. As the next step, we randomly excluded one case from each group and made 12 different combinations consisting of 7 responders and 11 nonresponders. We performed additional 12 permutation tests using the 12 combinations of the two groups.
Calculation of prediction score. We calculated prediction scores according to procedures described previously (13) . Each gene (gi) votes for either responder or non-responder depending on whether the expression level (x i ) in the sample is closer to the mean expression level of responders or nonresponders in reference samples. The magnitude of the vote (V i ) reflects the deviation of the expression level in the sample from the average of the two classes:
We summed the votes to obtain total votes for the responders (V r ) and non-responders (V n ) and calculated PS values as follows:
reflecting the margin of victory in the direction of either responder or non-responder. PS values range from -100 to 100; a higher absolute value of PS reflects a stronger prediction.
Evaluation of the classification and leave-one-out method.
We calculated the classification score (CS) using prediction scores of responders (PSr) and non-responders (PSn) in each gene set, as follows:
A larger value of CS indicates better separation of the two groups by the predictive-scoring system. For the leave-one-out test, one sample is withheld, the permutation P-value and mean expression levels are calculated using remaining samples and the class of the withheld sample is subsequently evaluated by calculating its prediction score. We repeated this procedure for each of the 20 samples.
Quantitative reverse transcription-PCR.
Aliquots of the same aRNA hybridized to the microarray slides from individual samples and from a mixture of pooled mRNA from normal ductal cells of 7 breast tissues were reversely transcribed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). Quantitative-RT-PCR were carried out using SYBR Premix Ex Taq (Takara, Ohtsu, Japan) on an ABI Prism 7700 Sequence Detection system (Applied Biosystems, Foster, CA), as described previously (14) . The sequences of primers used in the real-time PCR are shown in Table II . To normalize the expression of each gene, we selected as internal controls Sin3A-associated protein, 130 kDa (SAP130), NADH dehydrogenase (ubiquinone) 1 ß subcomplex, 8, 19 kDa (NDUFB8) and Chloride intracellular channel 1 (CLIC1) from among the 52 housekeeping genes because they showed the smallest Cy5/Cy3 fluctuations in our microarray data. Because normalization to these three endogenous control genes (SAP130, NDUFB8 and CLIC1) led to similar conclusions (data not shown), we subsequently recorded only the data normalized according to levels of SAP130 expression. For generation of standard curves we used a mixture of mRNAs derived from cancer samples from 20 patients. Quantitative RT-PCR experiments were done in duplicate for all 9 'predictive' genes and relative expression ratios of each sample were calculated. The normalized gene expression values were log-transformed (on a base 2 scale), in a manner similar to the transformation of microarray-based hybridization data.
Results
Identification of genes associated with docetaxel neoadjuvant chemotherapy. We enrolled 29 patients with breast cancer whose clinicopathological features are summarized in Table I . According to their responses to the treatment, we categorized the patients into two groups: 'responders', patients who achieved partial response (PR) after two courses of docetaxel neoadjuvant chemotherapy and 'non-responders', who revealed no shrinking of the tumors (SD or PD) after the chemotherapy.
To extract genes that were differentially expressed between the two groups, we first analyzed initial 20 samples (8 responders and 12 non-responders) by comparing expression levels of 36,864 transcripts. We carried out a random permutation test to identify genes that showed significantly different expression levels between the two groups and identified dozens of genes whose permutation P-values were <1x10 -4 and whose signal intensities were higher than the cutoff level in >60% of samples in at least one group (%presence >60). To further select the genes that more effectively distinguish the two groups, we performed 12 additional random permutation tests with twelve different combinations of 7 responders and 11 non-responders that were selected randomly, because the number of samples for this analysis was limited. As shown in Table III , LOC286109 and CENPT were selected by 11 tests; of course, the genes with smaller P-values in the primary random permutation test had a tendency to be selected frequently through these 12 additional tests. The additional random permutation tests further defined a set of 51 genes, which were commonly selected by more than four additional permutation tests and isolated by the same criteria as described above (P<1x10 -4 , %presence >60; Table III) . A supervised hierarchical clustering analysis using this set of genes with Cluster and Table I . Clinicopathological features of patients with breast cancer. 
ER, estrogen receptor; PgR, progesterone receptor; response, response to neoadjuvant docetaxel treatment; responder, patient who achieved partial response (PR) after two courses of treatment; PR, at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; nonresponder, patient who could not achieve complete response (CR) nor PR after two courses of treatment; SD (stable disease), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started; PD (progressive disease), at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; learning, samples used to develop the prediction system and test, samples used for test cases.
-----------------------------------------------------------------------------------------------------
Treeview software (http://rana.lbl.gov/EisenSoftware.htm) yielded good separation of the two groups with regard to the response to docetaxel (Fig. 1) .
Establishment of predictive scoring system for clinical response to docetaxel neoadjuvant chemotherapy.
Using the 51-gene set that seemed to effectively distinguish the two groups, we calculated the prediction score of each sample by the weighted-vote method (13). Then we rank-ordered these candidates on the basis of the number of selected times by twelve permutation tests (Table III) and calculated prediction scores by the leave-one-out test for cross-validation. For the leave-one-out test, we withheld one sample and calculated the permutation P-values and mean expression levels using the remaining samples to identify genes that were the most powerful for separating the two groups.
We calculated the classification score (CS) using the prediction scores of eight responders and twelve nonresponders in each gene set and obtained the best separation of the two groups by using the 9 genes that were ranked highest in our candidate gene list ( Fig. 2A and Table III) . A hierarchical clustering analysis using this set of genes with Cluster and Treeview software (http://rana.lbl.gov/Eisen Software.htm) yielded good separation of the two groups with regard to sensitivity to docetaxel neoadjuvant chemotherapy (Fig. 2B) .
Finally, to verify the prediction scoring system based on expression data for this set of 9 genes, we examined 9 'test' cases (2 responders and 7 non-responders; Fig. 2A ). We investigated gene expression profiles in each of the nine test cases and then calculated a prediction score for each sample. As shown in Fig. 2A , all of nine test-cases (two responders and seven non-responders) were correctly predicted their prediction scores that reflected their clinical response. Our data suggest that expression levels of these nine genes or a part of them might play important roles in cellular responses induced by the docetaxel neoadjuvant chemotherapy.
Establishment of a quantitative reverse transcription-PCRbased predictive scoring system. To further validate the results
of cDNA microarray analysis, we carried out real-time quantitative RT-PCR for the 9 predictive genes and three quantitative control genes, SAP130, NDUFB8 and CLIC1, using the 29 cases (20 learning and 9 test cases). We observed significant concordance between the results from the cDNA microarray and those of the quantitative RT-PCR experiments. As shown in Table IV , Pearson and Spearman rank correlations were positive and statistically significant for all of them.
Hence, we attempted to adapt our prediction system on the basis of quantitative RT-PCR for an easy clinical test. We performed quantitative real-time RT-PCR of the 9 predictive genes for 20 learning and 9 test cases (10 in responders and 19 in non-responders) and calculated the prediction score for each case. When we estimated these scores by the leave-oneout cross validation test, all cases were placed correctly according to their response to docetaxel neoadjuvant chemotherapy (Fig. 3) .
Discussion
cDNA microarrays are now widely used to analyze expression of thousands of genes simultaneously in cancer tissues. However, in our view, adequate attention has not been paid to the quality of the materials and experiments. For example, clinical samples (surgically resected tissue or biopsy materials) usually consist of various cellular components and the proportions of cancer cells in a given tissue can vary enormously from one tumor to another. Hence, most microarray data published previously are likely to be influenced significantly by heterogeneity of cell components in tumor tissues (15) . To obtain precise expression data of cancer cells, we applied a laser microbeam microdissection system to purify as much as possible the populations of cancer cells from biopsy specimens of 29 advanced breast cancers, with a view to establish a scoring system to predict response to docetaxel treatment. 
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Despite recent advances, 64-77% of patients with advanced breast cancer who received docetaxel chemotherapy showed no or very poor response in terms of staging and a large proportion of them suffer from adverse events such as alopecia, myelosuppression and/or gastrointestinal toxicity (16) (17) (18) . Although certain factors were reported to be associated with chemosensitivity or prognosis of breast cancer patients (17) (18) (19) , characterization of tumor natures using only one or a few of these factors has failed thus far to reliably predict individual responses, indicating a need for a more accurate method for predicting responses to anticancer drugs.
This study was designed to develop a prediction system for docetaxel neoadjuvant chemotherapy on the basis of gene expression profiles of purified populations of breast cancer cells. We identified 51 genes whose expression was significantly different between the responders and nonresponders and further ranked them by the number of selected times in twelve different random permutation tests that reflected a power to discriminate the two groups (P<0.0001; Table III ). Then we further selected nine genes and established the numerical scoring system. We further tested the scoring system by the leave-one-out cross validation method and found it to provide the best separation of the responders from the non-responders. Furthermore, our scoring system was able to predict accurately the response of all of nine additional test cases to the docetaxel neoadjuvant chemotherapy ( Fig. 2A) .
The list of 51 genes that showed significant differences between the two groups might provide insight into the biological mechanism(s) underlying sensitivity or resistance to docetaxel chemotherapy. Among those 51 genes, we found that cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1) was up-regulated in the responder group (Fig. 1 , Table III ). CYP2E1 has been identified as a source of reactive oxygen species in CYP2E1-dependent monooxygenation reactions. Moreover, CYP2E1 is the most active isozyme in the initiation of NADPH-dependent lipid peroxidation (20) . Oxidation of docetaxel by CYP2E1 was thought to influence the effects of docetaxel (21) . CYP2E1 up-regulation might increase the cytotoxicity of docetaxel, possibly due to increased production of lipid peroxides and oxygen radicals (22) . Thus, the level of CYP2E1 expression in a tumor could influence the extent of oxidation to reactive metabolites and in turn modify cytotoxic effects. Hence, up-regulation of CYP2E1 might contribute to response to docetaxel neoadjuvant chemotherapy among patients with breast cancer. Table III . List of 51 discriminating genes. On the other hand, in our experiments genes encoding chemokine (C-X3-C motif) receptor 1 (CX3CR1), Interleukin 6 (interferon, ß 2) (IL6) and Signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 (STAM2) were up-regulated in non-responders (Fig. 1, Table III) . CX3CR1 mediates the PI3-kinase/Akt pathway and activates ERK1 and ERK2 that are involved in cell survival and promote the anti-apoptosis activity (23) (24) (25) . It has been known that activation the PI3- Table III . Continued. 
a P-values were calculated by random permutation tests with responders (n=8) and non-responders (n=12).
b Plus indicate the genes up-regulated in responders and minus indicate the genes up-regulated in non-responders. c Number of selected times as significantly discriminating genes in twelve different random permutation tests. Information was retrieved from Unigene database in National Center for Biotechnology information.
- kinase/Akt pathway increases resistance to chemotherapy in cancer cells (26) (27) (28) . Hence, up-regulation of CX3CR1 might influence resistance to docetaxel neoadjuvant chemotherapy through activation of this cell-survival pathway. IL-6 is considered as a positive growth factor in cancer cells (29) . It was reported that autocrine production of IL-6 in breast cancer cells could confer multi-drug resistance in vitro through induction of multidrug resistance gene-1 transcription with subsequent overexpression of P-glycoprotein (PGP) (30) . Hence, up-regulation of IL-6 might influence resistance to docetaxel neoadjuvant chemotherapy. STAM2 has a unique structure containing a Src homology 3 (SH3) domain and a tyrosine cluster region including an immunoreceptor tyrosinebased activation motif (31). Furthermore, STAM2, which is associated with Jak2 and Jak3 tyrosine kinases, is implicated in playing a key role in the cell survival (32) . Thus, upregulated expression of STAM2 might contribute to resistance to docetaxel neoadjuvant chemotherapy through Jak/STAM/ c-myc pathway (33) .
Previously, other groups have predicted prognosis or chemosensitivity of tumors based on quantitative RT-PCR results for expression of genes selected through microarray analysis (34, 35) . To confirm the reliability of microarray data and establish more convenient prediction strategies for routine clinical use, we also performed quantitative RT-PCR experiments for 29 cases (20 learning cases and 9 test cases) of breast cancer using the nine selected predictive genes. We confirmed significant correlation between the data obtained by the microarray and those by the quantitative RT-PCR (Table IV) . Moreover, we verified that our quantitative RT-PCR-based prediction system could also correctly classify all of our subsequent test cases with regard to their drug responses (Fig. 3) . In any case, it should also be noted that the functions of 4 of our 9 predictive genes are still not well known. Therefore, further investigations will be needed to clarify their biological mechanisms associated with the response to docetaxel treatment.
In conclusion, we imply with some confidence that our prediction system for sensitivity of breast cancers to docetaxel therapy, on the basis of either the microarray-derived expression profiles or the quantitative RT-PCR results, should provide opportunities for achieving better prognosis and improved quality of life for patients, although a larger scale study is certainly warranted. Our data suggest that the goal of 'personalized medicine', prescribing the correct treatment regimen for each patient, may be achievable by selecting specific sets of genes for their predictive values according to the approach shown here. ----------------------------------------------------------------------------------------------- ------ 
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